Factor V (Arg506 → Gln) Mutation in Young Survivors of Myocardial Infarction

Thrombosis and Haemostasis

Volumn 75, Issue 5, 1996, Pages 701-702

  Ardissino, Diego ^a   Peyvandi, Flora ^b   Merlini, Piera Angelica ^c   Colombi, Elisabetta ^a   Mannucci, Pier Mannuccio ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IRCCS Maggiore Hospital

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 5; GLUTAMINE; MUTANT PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGE FACTORS; ARGININE; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MYOCARDIAL INFARCTION; POINT MUTATION;

EID: 0029943533     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650350     Document Type: Article

References (11)

1. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
2. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
3. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
4. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-7.
5. Hamsten A, Walldius G, Szamosi A, Blombäck M, de Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
6. Rees DC, Cox MC, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
7. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; ii: 986-8.
8. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-3.
9. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526-7.
10. 506→ Gln factor V mutation (factor V Leiden) in patients with cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
11. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer M, Eisenberg P, Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.